Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Marizyme's share price for the quarter that ended in Sep. 2024 was $0.04995. Marizyme's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 131.79 Mil. Therefore, Marizyme's market cap for the quarter that ended in Sep. 2024 was $6.58 Mil.
Marizyme's quarterly market cap
declined
from Mar. 2024 ($11.65 Mil) to Jun. 2024 ($7.13 Mil) and
declined
from Jun. 2024 ($7.13 Mil) to Sep. 2024 ($6.58 Mil).
Marizyme's annual market cap
declined
from Dec. 2021 ($71.73 Mil) to Dec. 2022 ($21.48 Mil) and
declined
from Dec. 2022 ($21.48 Mil) to Dec. 2023 ($13.19 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Marizyme's Enterprise Value for Today is $26.63 Mil.
Marizyme (OTCPK:MRZM) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Marizyme Market Cap Related Terms
Marizyme Market Cap Historical Data
* Premium members only.
The historical data trend for Marizyme's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Marizyme's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marizyme Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marizyme's Market Cap distribution charts can be found below:
* The bar in red indicates where Marizyme's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Marizyme's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marizyme (MRZM) has a Market Cap of $0.04 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Marizyme and its competitors.
Is Marizyme's Market Cap too high?
Marizyme's current Market Cap is $0.04 Mil. The Biotechnology industry median Market Cap is 114.03. Marizyme's value of $0.04 Mil is 100% below this industry median. Overall, Marizyme has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Marizyme's Market Cap compare to CNBX and XSNX?
Marizyme's Market Cap of $0.04 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 114.03. Marizyme's value of $0.04 Mil is 100% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.03, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marizyme's current Market Cap of $0.04 Mil is 100% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Marizyme and its competitors. For the Biotechnology industry, the median Market Cap is 114.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marizyme's current Market Cap is $0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marizyme stock overvalued right now?
Marizyme (MRZM) has a current Market Cap of $0.04 Mil. The current Market Cap is $0.04 Mil and 100% below the Biotechnology industry median of 114.03. Marizyme's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Marizyme (MRZM), the current Market Cap is $0.04 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
12GF Score
Get the complete analysis for MRZM
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRZM has been successfully added to your 
